CASE 01
Cross-Border Licensing of a Phase III AAV Gene Therapy
Territory: Eurasia (EAEU) & Europe
Cross-border licensing of a proprietary Chinese Phase III AAV gene therapy candidate across target EAEU and European jurisdictions, covering bridging clinical trial coordination, clinical material supply, and technology transfer for commercial-scale production.
Business Inquiries
Start a Cross-Border
Biopharma & Biotech Collaboration
Whether you are exploring cross-border pipeline licensing, custom automated bioprocess equipment, or supply chain integration in China, we welcome your inquiry. A managing partner for the relevant practice will respond within 3 business days.